Post-acute COVID-19 syndrome. Nalbandian A, et al, Nat Med 2021.
Notes sur les tags :
Réaliser des modifications :
Pour modifier ce document, il est nécessaire d'être connecté au site. Pour cela, assurez-vous d'avoir des identifiants valides. Si vous n'en avez pas,
contactez-nous. Pour vous connecter, cliquez sur l'icône
dans la barre de navigation.
Résumé et points clés
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patients recovering from COVID-19 grows, it is paramount to establish an understanding of the healthcare issues surrounding them. COVID-19 is now recognized as a multi-organ disease with a broad spectrum of manifestations. Similarly to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged effects after acute COVID-19. Patient advocacy groups, many members of which identify themselves as long haulers, have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of symptoms. Here, we provide a comprehensive review of the current literature on post-acute COVID-19, its pathophysiology and its organ-specific sequelae. Finally, we discuss relevant considerations for the multidisciplinary care of COVID-19 survivors and propose a framework for the identification of those at high risk for post-acute COVID-19 and their coordinated management through dedicated COVID-19 clinics.
Références de l'article
- Post-acute COVID-19 syndrome.
- Post-acute COVID-19 syndrome.
- Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY
- Nature medicine
- 2021
- Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22.
- Acute Disease, COVID-19/*complications/epidemiology/ethnology/therapy, Cardiovascular Diseases/epidemiology/therapy, Humans, Patient Advocacy, *SARS-CoV-2, Syndrome, Systemic Inflammatory Response Syndrome/epidemiology/therapy, Venous Thromboembolism/epidemiology/prevention & control
- COVID19, Long, LongCovid, PACS, COVID19
- Liens
- Traduction automatique en Français sur Google Translate
- DOI: 10.1038/s41591-021-01283-z
- PMID: 33753937
- Articles similaires
- Cité par
- Références
- Texte complet gratuit
- Twitter
- Twitter cet article (lien vers l'article)
- Twitter cet article (lien vers cette page)
Éditer la discussion
Références